Online inquiry

IVTScrip™ mRNA-Anti-MSTN, CSL-362-AML(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ6358MR)

This product GTTS-WQ6358MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets MSTN gene. The antibody can be applied in Acute myeloid leukemia (AML) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_005259.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2660
UniProt ID O14793
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MSTN, CSL-362-AML(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ6358MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15415MR IVTScrip™ mRNA-Anti-HAVCR2, TSR-022(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA TSR-022
GTTS-WQ15605MR IVTScrip™ mRNA-Anti-SLC29A2, VAL-1221(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA VAL-1221
GTTS-WQ7547MR IVTScrip™ mRNA-Anti-GPC3, GC33(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GC33
GTTS-WQ8803MR IVTScrip™ mRNA-Anti-PDCD1, IBI-308(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA IBI-308
GTTS-WQ3313MR IVTScrip™ mRNA-Anti-lukG&lukH, ASN-100(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ASN-100
GTTS-WQ5881MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, CIFN(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CIFN
GTTS-WQ12752MR IVTScrip™ mRNA-Anti-TIGIT, OMP-313M32(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA OMP-313M32
GTTS-WQ13040MR IVTScrip™ mRNA-Anti-IFNAR, Peg-IFNA2 R23(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA Peg-IFNA2 R23
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW